This small biotech company based in Sydney has taken a new...

This small biotech company based in Sydney has taken a new direction in further developing an Irritable Bowel Syndrome drug called Ibaconda. Ibaconda doesnt have a bigger dollar market share than Myoconda which is 2 Billion $US, Ibaconda market share is valued at 500 Million $US ...No#1

Myoconda was Giacondas lead drug and has just been sold for 1.5 million plus a 5% net royalty to Australian Medical Therapy Investments. At first I was a little surprised and disappointed at the sale for such a small amount of money. On the other hand the CEO has been trying to raise funding for the final stage for Myoconda for the pass 5 years with no success, with no cash in the bank this could not continue for ever.

I feel the CEO has taken Giaconda in a new better direction in a more marketable drug called Ibaconda which has a 27 million IBS suffers compared to Crohns disease sufferers of a million.

The problem with Ibaconda for Giaconda its in early stage of a clinical trial at stage IIa while Myoconda was at stage III. I really dont know how long it will take to get Ibaconda to stage III. I feel that this could take sometime as Im no expert on time lines for drug clinical trials but I feel that 12 month max to get to stage III if all goes well. According to Giaconda Ibaconda has a high success rate of 81% which is extremely promising.

Ibaconda Funding ..No#2
Since selling Myoconda Giaconda will have 1.5 Million to develop Ibaconda to go to market. If you read the announcement on March 2nd 2010 third paragraph

Under the Collaborative Research Agreement the CDD will assume control and the cost of the ongoing research and development of Ibaconda.

I feel that funding drug development in the pass was a major problem for Giaconda. Now with more funds things are looking more promising.


Future Share Prices
The top 20 share holders which have 85.2% last year it was 85.4% of the shares (one of the most tightly held shares in the ASX) It would not take much to see the share price move quickly with a good Ibaconda development announcement. Looking at the share price of just $00.05c and little share low liquidity it would not take much to see an increase in the share price. For example Giaconda gained 116.7% (+7c) to 13c over in a week, and while only 190,900 shares were traded in all In September 09.

Giacionda is a LONG term share investment with a good a few announcement(s) share will not be $00.05c a share, if youre looking for a quick buck forget it wont happen over night with Giaconda. It would be interesting to see the share price in 12 months time. Oh! Yes I own shares in Giaconda

Ibaconda Review From Giaconda No#3

Finally, we published a poser that was accepted by the Digestive Disease Week annual convention in Chicago last June. This, of course, was peer reviewed and published in the abstracts of the meeting and it demonstrated very significant results for Ibacondas combination of olsalazine and colchicine. Margauxs group did a retrospective analysis of 12 patients who had been on the therapy for their constipation for up to 22 months and ALL OF THEM responded to it. For over 81% of these patients, their problem was completely resolved. This is exciting news for the large number of people who have constipation predominate Irritable Bowel Syndrome. The global data shows that 9% of the population suffers from constipation problems in IBS and that is a very larger number for any therapy.



About Irritable Bowel Syndrome
Irritable Bowel Syndrome is a functional bowel disorder characterized by symptoms including abdominal pain or cramping, bloating, diarrhoea and / or constipation. 10-15% of the world population suffers from IBS. The cause of IBS remains unknown. IBS may be either diarrhoea-predominant or constipation-predominant or alternating between both. Approximately 9% of the worlds population suffers from IBS with constipation symptoms. There is currently no effective treatment or cure for IBS. Therapy may vary from a change in diet to the use of various medications, such as laxatives or drugs that change the motility of the bowel.While such treatments relieve symptoms for some patients, a large proportion of patients continue to suffer.

Ibaconda - A combination therapy for Irritable Bowel Syndrome
Ibaconda is a combination of olsalazine and colchicine which has been identified as providing effective relief to patients with constipation-predominant IBS when used in combination. Olsalazine is an anti-inflammatory medication currently used to treat ulcerative colitis that produces a laxative effect. Colchicine is a drug that has also demonstrated some efficacy when used to treat the symptoms of constipation. Both of these drugs when used as a single agent are only moderately effective in some patients. When used together these drugs provide more effective relief of constipation than either of the two drugs used alone. It is on this basis that Giaconda contends that
this combination offers an effective treatment alternative for patients with constipation-predominant IBS. Results of the use of this treatment at the Centre for Digestive Diseases reinforce this concept and are being further quantified through research.


Source
No#1
Myoconda Ibaconda Market Share
Slide 11 Giaconda 2008 AGM
http://www.giacondalimited.com/pdfs/AGM%20presentation.pdf


Source
No#2
Ibaconda Funding
Slide 21 Page 21 Giaconda 2009 AGM
http://www.asx.com.au/asxpdf/20100302/pdf/31p13tq1vlwxzt.pdf

Source
No#3
Ibaconda Review
Slide 21 Page 21 Giaconda 2009 AGM
http://www.asx.com.au/asxpdf/20091124/pdf/31m8f4bcn6g1l7.pdf

Information on Drug Clinical Trials
http://en.wikipedia.org/wiki/Clinical_trial